Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 6:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 32,711 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Oral Tablet Clear all
Completed Phase 1 Interventional

The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy

NCT01495962
View directory record Official record
Conditions
Wound; Abdomen, Abdominal Wall
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Rochester, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study

NCT04810962
View directory record Official record
Conditions
Ocular Inflammation and Pain After Cataract Surgery
Interventions
APP13007, 0.05%, Matching Vehicle Placebo for APP13007, 0.05%
Drug
Lead sponsor
Formosa Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
31
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Sep 30, 2026, 6:29 AM EDT
Not yet recruiting Phase 2 Interventional

SCI-110 in the Treatment of Tourette Syndrome

NCT05126888
View directory record Official record
Conditions
Tourette Syndrome
Interventions
SCI-110, Placebo
Drug · Other
Lead sponsor
Neurothera Labs Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 30, 2026, 6:29 AM EDT
Terminated Phase 2 Interventional

A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study

NCT00584688
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
quetiapine
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2012 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 3 Interventional Results available

The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

NCT03739203
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo, Antidepressant Therapy (ADT)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
58
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 4 Interventional Results available

A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients

NCT00770861
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
29
States / cities
Buena Park, California • Chino, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2011 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cherries Role in Gut Microbiota-liver-brain Function

NCT05586386
View directory record Official record
Conditions
Obesity
Interventions
Cherry group, Placebo group
Other
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Sep 30, 2026, 6:29 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

NCT04873869
View directory record Official record
Conditions
SCN8A Developmental and Epileptic Encephalopathy Syndrome
Interventions
NBI-921352, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
2 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
San Francisco, California • Washington D.C., District of Columbia • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate a Skeletal-muscle Microbiopsy Technique With Dynamic Proteomic Measurement in Healthy Male Volunteers

NCT01962454
View directory record Official record
Conditions
Cachexia
Interventions
Deuterated Water, Testosterone enanthate, Placebo to match testosterone enanthate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
60 Years to 75 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 30, 2026, 6:29 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

n-3 PUFA for Vascular Cognitive Aging

NCT01953705
View directory record Official record
Conditions
Age Related Cognitive Decline, Alzheimer's Disease, Vascular Dementia, Endothelial Dysfunction, Executive Dysfunction
Interventions
Omega 3 PUFA, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
75 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Sep 30, 2026, 6:29 AM EDT
Not yet recruiting Not applicable Interventional

Optimal Targeted High-definition Transcranial Direct Current Stimulation for Reducing Post-stroke Upper Limb Motor Impairments

NCT07599774
View directory record Official record
Conditions
Hemiparetic Stroke
Interventions
High-definition transcranial direct stimulation: sham, High-definition transcranial direct stimulation: optimal, Modified constraint-induced movement therapy
Device · Behavioral
Lead sponsor
Carle Foundation Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 30, 2026, 6:29 AM EDT
Not listed Phase 4 Interventional

The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils

NCT00673218
View directory record Official record
Conditions
Allergy
Interventions
Placebo, Xolair
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 6, 2012 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season

NCT02473510
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Trivalent Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
South Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Not applicable Interventional Results available

Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use

NCT01143259
View directory record Official record
Conditions
Ileus
Interventions
Alvimopam, 300 mg Polyethylene
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
American Fork, Utah • Cedar City, Utah • Logan, Utah + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers

NCT03836859
View directory record Official record
Conditions
Healthy Volunteers
Interventions
rhNGF 20μg/mL, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Sep 30, 2026, 6:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Gabapentin Premedication for ACL Reconstruction: RCT

NCT03417479
View directory record Official record
Conditions
Anterior Cruciate Ligament (ACL) Reconstruction
Interventions
Gabapentin
Other
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
12 Years to 18 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose

NCT03999996
View directory record Official record
Conditions
Dengue Fever
Interventions
Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV), Placebo
Biological
Lead sponsor
Takeda
Industry
Eligibility
13 Years to 63 Years
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
8
States / cities
Huntsville, Alabama • Peoria, Illinois • Newton, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 2 Interventional Results available

Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk

NCT02272946
View directory record Official record
Conditions
HIV, Cardiovascular Disease
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Priscilla Hsue, MD
Other
Eligibility
40 Years to 59 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Sep 30, 2026, 6:29 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing After Total Knee Arthroplasty (TKA)

NCT05823727
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
SOLUGEL, Placebo
Dietary Supplement
Lead sponsor
University of Arkansas
Other
Eligibility
50 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 2 Interventional

A 12-Week Study in Adult Subjects With Asthma

NCT01516086
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate (FP)
Drug
Lead sponsor
Dey
Industry
Eligibility
18 Years to 60 Years
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Rock Hill, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women

NCT02101970
View directory record Official record
Conditions
Breast Cancer
Interventions
Omega-3 Fatty Acids, Placebo Capsule, Diet and Exercise
Dietary Supplement · Other
Lead sponsor
Carol Fabian, MD
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Sep 30, 2026, 6:29 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

NCT07610473
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
DT-101, Placebo
Drug
Lead sponsor
Draig Therapeutics Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 30, 2026, 6:29 AM EDT
Withdrawn Phase 2 Interventional

Melatonin Supplementation to Improve Sleep in Patients With Heart Failure

NCT00869869
View directory record Official record
Conditions
Heart Failure, Sleep Disorders
Interventions
melatonin, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
35 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 3 Interventional

Phase 3 Study to Compare the Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media

NCT02044341
View directory record Official record
Conditions
Acute Otitis Media
Interventions
AR01, Glycerin ear drops
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
2 Months to 18 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
29
States / cities
Sheffield, Alabama • Tuscon, Arizona • Jonesboro, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Sep 30, 2026, 6:29 AM EDT